Global Liver Cancer Drug Market Size To Worth USD 7.6 Billion by 2033 | CAGR Of 10.90%

Category: Healthcare

RELEASE DATE Mar 2024
REPORT ID SI4058

A PHP Error was encountered

Severity: Notice

Message: Undefined variable: table

Filename: press/detail.php

Line Number: 118

Backtrace:

File: /home/admin/web/sphericalinsights.com/public_html/application/views/press/detail.php
Line: 118
Function: _error_handler

File: /home/admin/web/sphericalinsights.com/public_html/application/views/layouts/master_header_footer.php
Line: 687
Function: view

File: /home/admin/web/sphericalinsights.com/public_html/application/controllers/Press.php
Line: 89
Function: view

File: /home/admin/web/sphericalinsights.com/public_html/index.php
Line: 295
Function: require_once

Global Liver Cancer Drug Market Size To Worth USD 7.6 Billion by 2033

According to a research report published by Spherical Insights & Consulting, The Global Liver Cancer Drug Market Size is to grow from USD 2.7 Billion in 2023 to USD 7.6 Billion by 2033, at a Compound Annual Growth Rate (CAGR) of 10.90% during the projected period. 

Global Liver Cancer Drug Market

Get more details on this report -

Request Free Sample PDF

Browse key industry insights spread across 200 pages with 115 Market data tables and figures & charts from the report on the "Global Liver Cancer Drug Market Size, Share, and COVID-19 Impact Analysis, By Type (Hepatoblastoma, Hepatocellular Carcinoma, Cholangio Carcinoma, & Other), By Drug Class (Targeted Therapy, Immunotherapy, Chemotherapy, & Others), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2023 – 2033."  Get Detailed Report Description Here: https://www.sphericalinsights.com/reports/liver-cancer-drug-market

 

The drug used to treat liver cancer is referred to as the liver cancer drug. Many approaches, such as immunotherapies, traditional chemotherapy, and personalized treatments, have been researched. Serafenib is a well-known medication in this field that can be used to treat advanced hepatocellular carcinoma (HCC), the most frequent kind of liver cancer. Because it is a multi-kinase inhibitor, sorafenib stops the action of the enzymes that cause tumor development and angiogenesis. The rising incidence of liver cancer is one of the numerous forces driving the global market for liver cancer drugs. According to estimates made by the American Cancer Society, 41,000 Americans are expected to be diagnosed with primary liver cancer and intrahepatic bile duct cancer in 2023, affecting 27,980 men and 13,230 women.

 

The hepatocellular carcinoma segment is expected to hold the largest share of the global liver cancer drug market during the forecast period.   

On basis of the type, the global liver cancer drug market is divided into hepatoblastoma, hepatocellular carcinoma, cholangio carcinoma, and other. Among these, the hepatocellular carcinoma segment is expected to hold the largest share of the global liver cancer drug market during the forecast period. Because the most effective medicine for high liver cancer incidence is available to patients with hepatocellular carcinoma. According to estimates from the National Organization for Rare Diseases (NORD), there are around six new instances of HCC found in the general population for every 100,000 people in the United States.     

 

The targeted therapy segment is expected to hold the largest share of the global liver cancer drug market during the estimated timeframe.

Based on the drug class, the global liver cancer drug market is divided into targeted therapy, immunotherapy, chemotherapy and others. Among these, the targeted therapy segment is expected to hold the largest share of the global liver cancer drug market during the estimated timeframe. Research indicates that targeted therapies are more effective than traditional chemotherapy for the treatment of liver cancer. Studies have shown that when targeted therapy is administered, people with this illness typically survive longer.

 

North America is anticipated to hold the largest share of the global liver cancer drug market over the predicted timeframe.

 

North America

Get more details on this report -

Request Free Sample PDF

 

North America is anticipated to hold the largest share of the global liver cancer drug market over the predicted timeframe. Due to factors such growing awareness of liver cancer, the availability of insurance for drugs used to treat the condition, and active research and development programs, it is anticipated that the region will continue to hold its position as a leader during the projected period.

 

Throughout the projected period, Europe is anticipated to increase at the fastest rate. Increased funding for the creation of pharmaceuticals is thought to be the reason behind the pharmaceutical industry's growth in Europe. The market is expanding owing in part to targeted pharmaceutical therapeutic products.

 

Major vendors in the Global Liver Cancer Drug Market include, Bayer AG, Bristol-Myers Squibb Company, Eisai Co., Ltd., Exelixis, Inc., Merck KGaA, AbbVie, Amgen, Thermo Fisher Scientific, AstraZeneca, Johnson & Johnson, Sanofi SA, Novartis AG., and others.

 

Key Target Audience

  • Market Players
  • Investors
  • End-users
  • Government Authorities 
  • Consulting And Research Firm
  • Venture capitalists
  • Value-Added Resellers (VARs)

 

Recent Developments

  • In January 2022, in light of the findings of its second confirmatory research, Merck was given conditional authorization to market Keytruda, a medicine used to treat liver cancer.

 

 Market Segment

This study forecasts revenue at regional, and country levels from 2022 to 2033. Spherical Insights has segmented the Global Liver Cancer Drug Market based on the below-mentioned segments:

 

Global Liver Cancer Drug Market, By Type

  • Hepatoblastoma
  • Hepatocellular Carcinoma
  • Cholangio Carcinoma
  • Others

 

Global Liver Cancer Drug Market, By Drug Class

  • Targeted Therapy
  • Immunotherapy
  • Chemotherapy
  • Others

 

Global Liver Cancer Drug Market, By Region

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • Uk
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Middle East & Africa
    • UAE
    • Saudi Arabia
    • Qatar
    • South Africa
    • Rest of the Middle East & Africa

 

About the Spherical Insights & Consulting

Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.

Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements. 

 

CONTACT US:

For More Information on Your Target Market, Please Contact Us Below:    

Phone: +1 303 800 4326 (the U.S.)

Phone: +91 90289 24100 (APAC)

Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com

Contact Us: https://www.sphericalinsights.com/contact-us

Follow Us: LinkedIn | Facebook | Twitter

Need help to buy this report?

Inquiry Before Buy
We'll use cookies to improve and customize your experience if you continue to browse. Is it OK if we also use cookies to show you personalized ads?
Learn more and manage your cookies
Yes, Accept Cookies